Delving into the Latest Updates on Arsenic Trioxide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Arsenic oxide, Arsenic trioxide (JP17/USAN), Arsenic(III) oxide

+ [20]

Target

RARα

Action

antagonists

Mechanism

RARα antagonists(Retinoic acid receptor alpha antagonists)

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesOther Diseases+ [5]

Active Indication

Acute Promyelocytic LeukemiaChronic graft-versus-host diseaseScleroderma, Systemic+ [3]

Inactive Indication

Advanced Hepatocellular CarcinomaAnemia, RefractoryAnemia, Refractory, With Excess of Blasts+ [25]

Originator Organization

Cephalon LLC

Active Organization

Bone Therapeutics SA

Quetzal Therapeutics, LLC.Teva Pharmaceuticals Europe BV

+ [11]

Inactive Organization

Orsenix LLC

CTI BioPharma Corp.Mylan Ireland Ltd.

+ [3]

License Organization

Orsenix LLC

Medsenic SAS

Phebra Pty Ltd.

+ [4]

Drug Highest PhaseApproved

First Approval Date

United States (25 Sep 2000),

Acute Promyelocytic Leukemia

RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (South Korea), Orphan Drug (Australia)

Login to view timeline

Structure/Sequence

Molecular FormulaAs2O3

InChIKeyQTLQKAJBUDWPIB-UHFFFAOYSA-N

CAS Registry1327-53-3

This phase I trial tests the safety, side effects, best dose and how well arsenic trioxide works to prevent relapse in patients undergoing allogenic stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Chemotherapy drugs, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic trioxide may be safe, tolerable and/or effective in preventing relapse in patients undergoing allogenic stem cell transplant for AML or MDS.

Start Date01 Nov 2026

Sponsor / Collaborator

Rogel Cancer Center: University of Michigan

NCT07504458

/ RecruitingPhase 3

A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Start Date08 Jun 2026

Sponsor / Collaborator

Quetzal Therapeutics, LLC.

NCT07348107

/ Not yet recruitingPhase 1IIT

A Phase 1 Study of ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-L1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.

This study is testing whether adding three drugs, All-Trans Retinoic Acid (ATRA), SDK002 (also called Arsenic Trioxide or ATO), and tislelizumab, to standard chemotherapy is safe for people with advanced pancreatic cancer. Advanced pancreatic cancer means the cancer has spread or cannot be removed with surgery. The study will also look at whether this treatment combination may help people live longer.
Participants will receive standard chemotherapy drugs, gemcitabine and nab-paclitaxel, together with ATRA, SDK002, and tislelizumab. ATRA is related to vitamin A and may affect how cancer cells grow. SDK002 is a drug used to treat sine cancers and may help other treatments work better. Tislelizumab is an immunotherapy drug, which helps the immune system recognize and attack cancer cells. This is a phase 1 study, which means the main goal is to test safety and side effects. All participants receive the same treatment, and both the study doctors and participants know which drugs are being given.

Start Date15 Feb 2026

Sponsor / Collaborator

Sdk Therapeutics, Inc.

100 Clinical Results associated with Arsenic Trioxide

Login to view more data

100 Translational Medicine associated with Arsenic Trioxide

Login to view more data

100 Patents (Medical) associated with Arsenic Trioxide

Login to view more data

3,646

Literatures (Medical) associated with Arsenic Trioxide

31 Dec 2026·ANNALS OF MEDICINE

Acute leukemia during pregnancy: a single center experience with 23 cases, 2012–2022 and literature review

Review

Author: Zhao, Xie-Lan ; Chen, Cong ; Guo, Jiamin ; Fu, Xiao ; Liu, Yi ; Gai, Dongzheng ; Liu, Wei ; Rosen, Steven T. ; Chen, Fangping ; Zhang, Kai-Xuan

BACKGROUND AND OBJECTIVE:

Acute Leukemia (AL) diagnosed during pregnancy is uncommon, and the management of AL complicated by pregnancy is a poorly studied area that faces a therapeutic dilemma.

METHOD:

23 cases diagnosed with AL during pregnancy were collected from our center between 2012 and 2022. Additionally, we summarized 17 clinical studies on AL diagnosed during pregnancy.

RESULT:

Sixteen AML and seven ALL patients were diagnosed during pregnancy in our center; most patients diagnosed during the first or second trimester tended to receive chemotherapy after abortion. All patients diagnosed during the third trimester opted to defer therapy until after delivery. The rate of overall response rate (ORR) was 77.3%, which was found to be similar to that of the general population. A Short delay in initiating anti-leukemia treatment is not associated with a negative impact on prognosis. We conducted a meta-analysis of the literature, and the summary relative complete remission (CR) rate was 76.9% (95%CI 69.1-84.6%) (Random Effects Model I^2 = 66%, p <0.001). We included four Chinese studies comprising 135 participants for further analysis. For non-M3 AL patients, CR rate of the chemotherapy-first cohort was 63.6%, compared with 68.6% in the treatment-after-delivery or abortion cohort (p = 0.657). For M3 patients, the rate was 100 and 83.3%, respectively (p < 0.001).

CONCLUSION:

Our findings suggest that for non-M3 AL patients can sometimes be managed during pregnancy. For M3 patients, early treatment potentially yield favorable outcomes for both the mother and fetus, using ATRA-based regimens without arsenic trioxide (in the second and third trimester) or standard chemotherapy (in the second trimester) may be considered a treatment option.

31 Dec 2026·Journal of the International Society of Sports Nutrition

Association between usual protein intake and muscle function in older U.S. adults: a target-trial emulation using NHANES 2011–2018

Article

Author: Ling, Yang ; Riaz, Muhammad ; Hou, Ming-Xuan ; Rahman, Najm Ur

BACKGROUND:

The link between long-term protein intake and muscle performance in older adults has been hard to define, partly because most studies rely on short dietary windows and are vulnerable to confounding and measurement noise. In this work, we attempted to estimate the usual protein intake and functional limitation among U.S. adults aged ≥ 60 years using a target-trial emulation framework with overlap weighting and semiparametric estimators.

METHODS:

Data were drawn from four NHANES survey cycles (2011-2018), including 5,736 adults aged ≥ 60 years with complete exposure, outcome, and covariate data. Usual protein intake (g/kg/day) was derived from available 24-hour recalls to approximate habitual intake. The primary outcome was PFQ-defined mobility limitation across cycles; grip strength (2011-2014) was analyzed separately as a secondary outcome. Causal contrasts across predefined intake categories (<0.8, 0.8- < 1.0, 1.0- < 1.2, ≥1.2 g/kg/day) were evaluated using covariate-balancing propensity score overlap weighting (ATO estimand) followed by marginal structural models. Doubly robust sensitivity analyses were conducted using augmented inverse probability weighting and targeted maximum likelihood estimation with generalized linear models. Simulation extrapolation (SIMEX) was applied to assess potential bias from dietary measurement error. Exploratory analyses evaluated hs-CRP as a potential mediator and tested effect modification by vitamin D status and physical activity.

RESULTS:

Mean usual protein intake was 0.93 g/kg/day, and approximately 42% of participants consumed at least 0.8 g/kg/day, the current Recommended Dietary Allowance (RDA) for the general adult population. In the prespecified overlap-weighted marginal structural model (ATO estimand), higher intake was associated with lower odds of mobility limitation, although the primary contrast comparing ≥ 1.2 versus < 0.8 g/kg/day was modest and not statistically significant (OR 0.89, 95% CI 0.54-1.47). A doubly robust binary contrast yielded a -6.6 percentage-point difference in predicted limitation (95% CI -25.8 to 12.7), consistent in direction but imprecise. In cycle-specific analyses, the inverse association was more pronounced in 2015-2018 (OR 0.80, 95% CI 0.65-0.98). Spline models suggested a steeper decline in predicted limitation below approximately 1.0-1.1 g/kg/day, with a flatter trajectory at higher intakes. Exploratory mediation models indicated a potential indirect component through hs-CRP, though these estimates were not overlap-weighted and should be interpreted cautiously.

CONCLUSIONS:

Higher usual protein intake was directionally associated with lower odds of mobility limitation among older U.S. adults within a target trial emulation framework, although the primary overlap-weighted estimates were modest and imprecise. Evidence of nonlinearity suggests that intakes near 1.0-1.1 g/kg/day may mark a range where predicted limitation declines more steeply, but uncertainty increases at higher intake levels. Given the cross-sectional design and residual potential for confounding, these findings should be interpreted cautiously. Prospective studies are needed to determine whether sustained protein intake in this range meaningfully preserves functional capacity over time.

01 Oct 2026·BIOMATERIALS

A hybrid nanoadjuvant cascading activation of the cGAS-STING-IFN-Ⅰ pathway to enhance radio-immunotherapy

Article

Author: Li, Yin ; Zhang, Xiangyang ; Shen, Jianliang ; Cui, Guangzu ; Zhou, Zaigang ; Zeng, Shan ; Fei, Jiang ; Zhang, Peng ; Jiang, Zhaohui ; Wang, Kailing ; Han, Ying ; Shen, Hong ; Wang, Xinwen ; Liu, Yongting

The cGAS-STING signaling pathway is crucial for radiotherapy (RT)-induced immune modulation. However, under hypoxic conditions, reduced DNA damage and enhanced DNA damage repair (DDR) lead to lower cytosolic double-stranded DNA (dsDNA) levels, making standard RT doses inadequate for sustained cGAS-STING activation, resulting in transient immune responses. In this study, we developed the As-Mn@MnO₂@Alb nanosystem as a potent radiosensitizer and cGAS-STING pathway amplifier. Arsenic trioxide (ATO)-mediated radiosensitization suppresses DDR, enhances immunogenic cell death, and increases tumor-associated antigens and cytosolic dsDNA levels. Concurrently, degradable MnO₂ releases Mn²⁺ in tumors, boosting cGAS recognition and sensitivity, while generating oxygen to alleviate hypoxia and improve RT efficacy. The synchronized delivery of Mn²⁺ and accumulated cytosolic dsDNA amplifies cGAS-STING activation, promoting dendritic cell (DC) maturation, enhancing CD8⁺ T cell infiltration, reducing immunosuppressive Treg infiltration, and significantly inhibiting both irradiated local tumors and non-irradiated distal CRC tumors while inducing robust immune memory effects, all with no notable toxicity. This study demonstrates that effective RT sensitization, coupled with synchronized STING activation, represents a robust strategy to overcome radio-immunotherapy resistance in colorectal cancer.

185

News (Medical) associated with Arsenic Trioxide

11 Jun 2026

·www.biospace.com

Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia

CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company’s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL. "Dosing the first patient in QUATRO-APL is an important clinical development milestone for Quetzal," said Usman Ahmed, Chief Executive Officer and Chairman of Quetzal Therapeutics. "We look forward to continued enrollment and to working with our investigators, clinical sites, and partners as the trial progresses." "Current standard-of-care regimens for APL require a significant number of intravenous infusions over the course of therapy, which can be burdensome for patients and healthcare systems," said Shaad Abedin, M.D., Chief Medical Officer of Quetzal Therapeutics. "QUATRO-APL is designed to evaluate whether an oral formulation of arsenic trioxide can offer a potential alternative to intravenous administration. We are grateful to the investigators, site teams, and partners whose commitment made this milestone possible." Quetzal Therapeutics expects continued site activation and patient enrollment across the United States and Europe as the global Phase 3 program advances and plans to provide additional updates on study progress as enrollment continues. About the QUATRO-APL Trial QUATRO-APL (QTX-2101-301) is a pivotal, open-label Phase 3 clinical study evaluating the efficacy, safety, and pharmacokinetics of QTX-2101, an oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), in adult patients with newly diagnosed, low-risk acute promyelocytic leukemia. The comparator arm is intravenous arsenic trioxide plus ATRA. Additional information is available at ClinicalTrials.gov (NCT07504458) and the EU Clinical Trials Information System (2025-524810-28-00). About Acute Promyelocytic Leukemia APL is a rare and aggressive subtype of acute myeloid leukemia, accounting for approximately 10-15% of all AML cases. It is defined by the PML-RARA gene fusion and is associated with severe bleeding complications and rapid disease progression if untreated. While advances in therapy have transformed outcomes, current treatments often require patients to undergo a large number of lengthy intravenous infusions over the course of therapy. This relentless treatment schedule can disrupt daily life and place a significant burden on both patients and their support networks. There remains a clear need for innovative and more accessible therapies. About Quetzal Therapeutics Quetzal Therapeutics is a biopharmaceutical company dedicated to developing treatment for rare diseases, including hematologic malignancies. The company’s lead product is QTX-2101, a novel, investigational approach for treating patients with APL. Quetzal is also advancing QTX-2102, a pre-clinical, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. QTX-2101 is an investigational, oral capsule formulation of arsenic trioxide . It is being evaluated as a potential oral alternative to intravenous arsenic trioxide. QTX-2101 has been granted Orphan Drug Designation by the U.S. FDA and the European Commission, as well as FDA Fast Track designation. QTX-2101 has not been approved by any regulatory authority, and its safety and efficacy have not been established. This press release contains forward-looking statements reflecting current expectations for ongoing development, which may evolve over time. For more information, please visit: Media Contact: info@quetzaltx.com

30 Jan 2026

·www.biospace.com

QTX-2101 Awarded FDA Fast Track Designation for the Treatment of Acute Promyelocytic Leukemia

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing treatments for rare diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101 , the company’s investigational oral arsenic trioxide capsule, for the treatment of patients with acute promyelocytic leukemia (APL) . QTX-2101 is an oral capsule formulation of arsenic trioxide developed with the goal of addressing limitations associated with intravenous administration, including the need for frequent clinic visits. The potential for QTX-2101 to simplify treatment administration while maintaining precise dosing and stability is under investigation. QTX-2101 is currently being evaluated in a global, multicenter, randomized, controlled Phase III clinical trial comparing the investigational oral capsule to standard-of-care therapy in patients with newly diagnosed APL. The trial builds on pharmacokinetic and safety data from prior Phase I studies conducted in the United States. The Fast Track designation is intended to facilitate the development and expedite the review of investigational therapies for serious conditions, underscoring the severity of APL and the continued unmet medical need despite an effective standard of care therapy. This designation allows for more frequent interaction with the FDA as the clinical development of QTX-2101 progresses, and may enable a more efficient registration filing upon positive data. The therapy remains investigational, and its safety and efficacy have not yet been established. Fast Track designation does not change the standards for approval and does not guarantee that QTX-2101 will receive FDA approval. About Acute Promyelocytic Leukemia (APL) APL is a rare and aggressive subtype of acute myeloid leukemia, accounting for approximately 10-15% of all AML cases. It is defined by the PML-RARA gene fusion and is associated with severe bleeding complications and rapid disease progression if untreated. While advances in therapy have transformed outcomes, current treatments often require patients to undergo a large number of lengthy intravenous infusions over the course of therapy. This relentless treatment schedule can disrupt daily life and place a significant burden on both patients and their support networks. There remains a clear need for innovative and more accessible therapies. About Quetzal Therapeutics Quetzal Therapeutics is a biopharmaceutical company dedicated to developing treatment for rare diseases, including hematologic malignancies. The company’s lead product is QTX-2101, a novel approach for treating patients with APL. Quetzal is also advancing QTX-2102, a pre-clinical, next-generation antifungal and antiparasitic therapy designed to enhance efficacy while minimizing toxicity. QTX-2101 is an investigational, oral arsenic trioxide therapy that has not yet been approved by any regulatory authority. Its safety and efficacy are currently under evaluation. This press release contains forward-looking statements reflecting current expectations for ongoing development, which may evolve over time. For more information, please visit: Media Contact: info@quetzaltx.com

Fast TrackPhase 3Phase 1

18 Jul 2025

·endpoints.news

Bristol Myers Squibb’s Reblozyl fails Phase 3 in anemia; Sanofi, Blueprint deal closes

Plus, news about DiaMedica Therapeutics, Cantargia and Quetzal Therapeutics: Bristol Myers Squibb suffers late-stage miss in anemia: Patients with myelofibrosis-associated anemia taking Reblozyl were no more able than those on placebo to go three months without a red blood cell transfusion in a Phase 3 trial. There was a numerical and clinically meaningful improvement in transfusion independence favoring the product, which is intended to boost levels of a patient’s native red blood cells, BMS said . However, this was not significant at p=0.0674. BMS said it was “encouraged” by the results and would discuss filing plans with regulators. — Elizabeth Cairns Sanofi closes $9.1B acquisition of Blueprint Medicines: It’s the second largest biopharma deal of the year after Johnson & Johnson’s $14.6 billion buyout of Intra-Cellular Therapies in January. — Jaimy Lee DiaMedica Therapeutics’ Phase 2 success in pre-eclampsia: The biotech’s DM199 achieved prespecified safety and efficacy endpoints in the dose-escalation part of the mid-stage study, including dose-dependent reductions in systolic and diastolic blood pressure. There were no cases of placental transfer and no serious side effects in any cohort, the company said Thursday. — Ayisha Sharma Cantargia’s IL1RAP antibody flops: An open-label Phase 1b/2 study found a 40% overall response rate (ORR) among triple-negative breast cancer patients taking the Swedish biotech’s nadunolimab plus carboplatin and gemcitabine. It also produced a 43% ORR in a control group taking the latter two drugs. Addition of the drug did not alter the chemo’s safety profile, according to Cantargia. — Elizabeth Cairns Quetzal Therapeutics launches with $50M: The company has two assets: QTX-2101, a mid-stage oral arsenic trioxide therapy for acute promyelocytic leukemia, and QTX-2102, a preclinical antifungal and antiparasitic therapy. It’s run by Usman Ahmed, the former CEO of Nexus Pharmaceuticals. — Jaimy Lee

Clinical ResultPhase 3AcquisitionPhase 2

100 Deals associated with Arsenic Trioxide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02106	Arsenic Trioxide	L01XX27	DB01169

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Promyelocytic Leukemia	United States	Cephalon LLC	25 Sep 2000

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 3	United States	Cephalon LLC	01 Oct 2007
Acute Myeloid Leukemia	Phase 3	Canada	Cephalon LLC	01 Oct 2007
Systemic Lupus Erythematosus	Phase 2	France	Medsenic SAS	01 Jul 2013
Small Cell Carcinoma	Phase 2	United States	Teva Pharmaceuticals USA, Inc.	01 Aug 2011
Small Cell Carcinoma	Phase 2	United States	Cephalon LLC	01 Aug 2011
Small Cell Lung Cancer	Phase 2	United States	Cephalon LLC	01 Aug 2011
Small Cell Lung Cancer	Phase 2	United States	Teva Pharmaceuticals USA, Inc.	01 Aug 2011
Metastatic endometrial cancer	Phase 2	United States	Cephalon LLC	01 Mar 2010
uterus adenocarcinoma	Phase 2	United States	Cephalon LLC	01 Mar 2010
Glioma	Phase 2	United States	Cephalon LLC	01 May 2005

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Acute Promyelocytic Leukemia	1,134	ATRA+ATO combined with gemtuzumab ozogamicin (GO) or low-dose anthracycline	cumazvblbn(hskjlxvmhe) = jhxkcspglr avjfiuwehp (onyptsgipe, 4.7 - 15.9) View more	Positive	29 May 2026
				ATRA-based therapy with ≥3 anthracycline doses	cumazvblbn(hskjlxvmhe) = hpdjimohkr avjfiuwehp (onyptsgipe, 6.8 - 15.5) View more
EHA2026	Not Applicable	Acute Promyelocytic Leukemia	72	ATRA+ATO	oczjlfnnzk(dxofxxbwdz) = xyybyxltrh ixtvpafxig (osennylghc ) View more	Positive	12 May 2026
JPRN-jRCTs041190101 (APL219R, EHA2026)	Phase 2	CD33-positive	39	Tamibarotene+Arsenic trioxide+Gemtuzumab ozogamicin	mnzanqwsfb(jmbwmgogpe) = ijskjyfwpb vrrckzbvxe (ftpbfysapq ) View more	Positive	12 May 2026
APOLLO (EHA2026)	Phase 3	Acute Promyelocytic Leukemia	133	all-trans retinoic acid and arsenic trioxide (ATRA/ATO)	qlzhnbtfgd(vtlmjmaxei) = nagmkcdvds pewakioglo (wgoivfljwl, 73 - 94) View more	Superior	12 May 2026
				ATRA plus idarubicin (AIDA)	qlzhnbtfgd(vtlmjmaxei) = yggefekyij pewakioglo (wgoivfljwl, 52 - 79) View more
ASH2025	Not Applicable	Acute Promyelocytic Leukemia	64	ATRA + arsenic-based regimens	usetkuvgmb(huikkvpqcf) = gjylldqlyo nnoblinjfp (qzhjyiblih ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Acute Promyelocytic Leukemia	26	ATRA+ATO/RIF+venetoclax	krsnrvhmug(pwrpagbnqh) = iqbuestnel kmstdesaci (xunwpgkyuc ) View more	Positive	06 Dec 2025
NCT02688140 (APOLLO, Pubmed \| J Clin Oncol)	Phase 3	Acute Promyelocytic Leukemia First line	133	Arsenic Trioxide + All-Trans Retinoic Acid + Idarubicin	awhcyftxhv(fzrksgswyu) = ldsqovceuz nijozcttew (dgcxnkikqz )	Positive	10 Oct 2025
				Standard All-Trans Retinoic Acid + Anthracycline-Based Chemotherapy	awhcyftxhv(fzrksgswyu) = csyhhzuonj nijozcttew (dgcxnkikqz )
PF538 (EHA2025)	Not Applicable	Acute Promyelocytic Leukemia	156	Standard-dose ATO group	pmzvicswmk(ghtvnreysj) = ujuzjyhkju kjgwimgitr (ivldxozwkg ) View more	-	14 May 2025
				Low-dose ATO group	pmzvicswmk(ghtvnreysj) = uuqejukgjw kjgwimgitr (ivldxozwkg ) View more
ASH2024	Not Applicable	Acute Promyelocytic Leukemia	-	Standard-dose ATO (10mg IV daily for 28 days)	xvcqsvmryw(pemiybkywu) = Patients receiving ATO treatment have a high rate of adverse events in both groups, reducing the total ATO dosage at induction treatment may reduce the adverse event rate and help patients achieve the same long-term survival. rpogitmvoy (nfstgykjaz )	-	09 Dec 2024
				Low-dose ATO (10mg IV daily for less than 28 days)
ESMO_ASIA2024	Not Applicable	Acute Promyelocytic Leukemia Consolidation	19	ATRA, ATO, DNR	nwuubaasdu(scyvvqujxu) = 6 patients wmiyxduapo (cfquyvxoqf ) View more	Positive	07 Dec 2024